Addition of bezafibrate beneficial in primary biliary cholangitis

June 13, 2018

(HealthDay)—Nearly one-third of patients with primary biliary cholangitis who had had an inadequate response to ursodeoxycholic acid alone achieved a complete biochemical response with the addition of bezafibrate to treatment, according to a study published online June 7 in the New England Journal of Medicine.

Christophe Corpechot, M.D., from Saint-Antoine University Hospital in Paris, and colleagues randomly assigned 100 patients with primary biliary cholangitis who had had an inadequate response to ursodeoxycholic acid to receive either bezafibrate (400 mg daily) or , plus continued treatment with ursodeoxycholic acid.

The researchers found that 31 percent of the patients assigned to bezafibrate had a complete biochemical response (normal levels of total bilirubin, alkaline phosphatase, aminotransferases, and albumin as well as a normal prothrombin index) versus none assigned to placebo. Changes in pruritus, fatigue, and noninvasive measures of fibrosis, including liver stiffness and Enhanced Liver Fibrosis score, paralleled the biochemical responses. Two patients in each group had complications from end-stage liver disease, while myalgia occurred more often in the bezafibrate group than the placebo group (20 versus 10 percent).

"Among with primary biliary cholangitis who had had an inadequate response to ursodeoxycholic acid alone, treatment with bezafibrate in addition to ursodeoxycholic acid resulted in a rate of complete biochemical response that was significantly higher than the rate with placebo and ursodeoxycholic acid therapy," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; the study was funded in part by Arrow Génériques.

Explore further: Trial of fibrate therapy in primary biliary cholangitis shows treatment is well tolerated

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Trial of fibrate therapy in primary biliary cholangitis shows treatment is well tolerated

April 22, 2017
The results of the BEZURSO study, presented today, found that bezafibrate in combination with UDCA normalised prognostic markers of liver disease in patients with primary biliary cholangitis (PBC) with an inadequate response ...

Budesonide add-on therapy improves markers of disease activity but fails to improve histology

April 13, 2018
The addition of budesonide is associated with clinically meaningful improvements in biochemical markers of disease activity but no improvement in liver histology in high-risk patients with primary biliary cholangitis (PBC) ...

Phase 2 studies of two novel treatments for primary biliary cholangitis report encouraging results

April 13, 2018
Preliminary results from two ongoing Phase 2 studies of novel agents under investigation for the treatment of primary biliary cholangitis (PBC) have suggested promising efficacy, safety and tolerability profiles in patients ...

FDA approves ocaliva for primary biliary cholangitis

June 1, 2016
(HealthDay)—Ocaliva (obeticholic acid) has been approved by the U.S. Food and Drug Administration to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response ...

Long-term obeticholic acid treatment leads to reversal or stabilization of fibrosis/cirrhosis in patients with PBC

April 13, 2018
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid (OCA) leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis ...

Obeticholic acid produces meaningful biochemical and clinical improvements in PBC cirrhosis patients

April 12, 2014
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had ...

Recommended for you

Recent clinical trial finds tamsulosin not effective in kidney stone passage

June 18, 2018
The latest research into finding medications to aid the passage of ureteral or kidney stones has shown that tamsulosin is not effective for patients across the board. Previously approved to help men experiencing enlarged ...

Research finds new way to determine protection of Men B vaccine against different strains

June 18, 2018
Researchers at the University of Leicester and Meningococcal Reference Unit have developed a new approach to assess the effectiveness of the Men B vaccine, Bexsero, against different strains that cause meningococcal meningitis ...

Novel molecular target to prevent scarring of the lung blood vessels identified

June 13, 2018
Pulmonary arterial hypertension, a severe form of cardiopulmonary disease in which the arteries that transport blood from the heart to the lungs become thickened, constricted, and scarred, is a disease for which there is ...

Lineage of TB traced and compared to early human migration

June 13, 2018
A team of researchers from the University of Wisconsin, the University of Iowa and the Norwegian Institute of Public Health has carried out genetic studies of tuberculosis to learn more about its lineage and to compare it ...

Fast-acting cholera vaccine could curb outbreaks

June 13, 2018
A tricked-out cholera vaccine starts protecting against the deadly disease within a day, experiments in rabbits suggest. The rapid protection offered by this designer vaccine may one day limit the spread of cholera outbreaks, ...

Finally, hope for a syphilis vaccine

June 12, 2018
Despite efforts to eradicate it, syphilis is on the rise. Until now, most health agencies focused on treating infected people and their sex partners but new discoveries may make a vaccine possible, UConn Health researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.